Crossmark

Protein condensation diseases: therapeutic opportunities

Crossref DOI link: https://doi.org/10.1038/s41467-022-32940-7

Published Online: 2022-09-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vendruscolo, Michele http://orcid.org/0000-0002-3616-1610
Fuxreiter, Monika http://orcid.org/0000-0002-4463-6727
License Information

Text and Data Mining valid from 2022-09-22

Version of Record valid from 2022-09-22
More Information

Article History

Received: 12 March 2022

Accepted: 23 August 2022

First Online: 22 September 2022

Competing interests

: M.V. is a founder of Wren Therapeutics. M.F. declares no competing interests.